Phase 2 Muscular Dystrophy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children in different age groups may be eligible, ranging from newborns up to under 18 years old, depending on which part of the trial (cohort) they would join.
- Depending on the cohort, participants may need to be able to walk and complete a 10-meter walk or run test in under 30 seconds, or may be eligible even if they can no longer walk (confirm with trial site for your specific group).
- Participants must have a confirmed diagnosis of Duchenne Muscular Dystrophy (DMD) with a specific gene change that causes DMD, verified by the trial's own genetic testing.
- Participants must test negative for antibodies to a certain virus used in the gene therapy (AAV antibodies).
- Most cohorts require participants to have been on a stable daily steroid dose (prednisone or deflazacort) for at least 12 weeks before joining, though this does not apply to the youngest age group (confirm with trial site).
- Participants must meet certain physical performance test requirements relevant to their cohort (confirm with trial site for details).
- Participants must weigh 90 kg (about 198 pounds) or less.
Who may not be able to join:
- People who have taken drugs that affect dystrophin (a key muscle protein) within the last 3 months before screening.
- People who have previously received or are currently receiving any approved or experimental gene therapy.
- People who have taken certain other approved or experimental drugs within the last 3 months (or longer, depending on the drug) before screening.
- People whose DMD is caused by a specific type of gene deletion affecting certain sections of the DMD gene (exons 1–11, 42–45, or 57–69), as confirmed by genetic testing.
- Other eligibility requirements may also apply that are not listed here (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Solid Bio Clinical Trials, Solid Biosciences
Phone: 617-337-4680
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of treatment-emergent adverse events (AEs); Change from baseline in Microdystrophin Protein Levels
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.